Please login to the form below

Not currently logged in
Email:
Password:

Medivir appoints Actelion's Henric Juserius to senior commercial role

As executive vice president, commercial he will head up all the company's activities in the area

Medivir has appointed Actelion's Henric Juserius to head up its commercial activities and join its management team.

Juserius will move to the Swedish specialty pharma company in August from Actelion, where he was most recently commercial director for the Nordic region.

He has more than 20 years' experience in pharmaceutical marketing and sales, gained from companies such as Astra, GlaxoWellcome, Pfizer, Serono and Actelion.

Maris Hartmanis, Medivir's president and CEO, said: "I am very pleased to welcome Henric Juserius to Medivir as executive vice president, commercial.

“His extensive experience and broad expertise in marketing and sales of prescription drugs from both large and small pharmaceutical companies will be invaluable now that Medivir is approaching a market launch in the Nordic countries of its flagship product for hepatitis C, TMC435.”

The drug is a novel protease inhibitor in phase III clinical trials for hepatitis C that Medivir is developing in collaboration with Janssen Pharmaceuticals.

Meanwhile, the firm's first product, OTC cold sore treatment Xerese/Xerclear, is approved in Europe, where Medivir is launching it in partnership with GlaxoSmithKline.

15th May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics